BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Helmi O, Elshishiny F, Mamdouh W. Targeted doxorubicin delivery and release within breast cancer environment using PEGylated chitosan nanoparticles labeled with monoclonal antibodies. Int J Biol Macromol 2021;184:325-38. [PMID: 34119547 DOI: 10.1016/j.ijbiomac.2021.06.014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Ying N, Lin X, Xie M, Zeng D. Effect of surface ligand modification on the properties of anti-tumor nanocarrier. Colloids and Surfaces B: Biointerfaces 2022;220:112944. [DOI: 10.1016/j.colsurfb.2022.112944] [Reference Citation Analysis]
2 Dudoitis V, Gylienė O, Dementjev A, Mordas G, Plauškaitė-šukienė K, Byčenkienė S, Jasinevičienė D, Ulevičius V. Fabrication of Chitosan-Palladium Nanoparticles by Liquid Atomization. J Polym Environ 2022. [DOI: 10.1007/s10924-022-02665-1] [Reference Citation Analysis]
3 Wang J, Heshmati Aghda N, Jiang J, Mridula Habib A, Ouyang D, Maniruzzaman M. 3D bioprinted microparticles: Optimizing loading efficiency using advanced DoE technique and machine learning modeling. International Journal of Pharmaceutics 2022;628:122302. [DOI: 10.1016/j.ijpharm.2022.122302] [Reference Citation Analysis]
4 Ashrafizadeh M, Hushmandi K, Mirzaei S, Bokaie S, Bigham A, Makvandi P, Rabiee N, Thakur VK, Kumar AP, Sharifi E, Varma RS, Aref AR, Wojnilowicz M, Zarrabi A, Karimi‐maleh H, Voelcker NH, Mostafavi E, Orive G. Chitosan‐based nanoscale systems for doxorubicin delivery: Exploring biomedical application in cancer therapy. Bioengineering & Transla Med. [DOI: 10.1002/btm2.10325] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Soltani A, Faramarzi M, Farjadian F, Parsa SAM, Panahi HA. pH-responsive glycodendrimer as a new active targeting agent for doxorubicin delivery. Int J Biol Macromol 2022;221:508-22. [PMID: 36089082 DOI: 10.1016/j.ijbiomac.2022.09.037] [Reference Citation Analysis]
6 Wu SY, Wu FG, Chen X. Antibody-Incorporated Nanomedicines for Cancer Therapy. Adv Mater 2022;:e2109210. [PMID: 35142395 DOI: 10.1002/adma.202109210] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
7 Wang J, Maniruzzaman M. A global bibliometric and visualized analysis of bacteria-mediated cancer therapy. Drug Discov Today 2022:S1359-6446(22)00214-8. [PMID: 35654388 DOI: 10.1016/j.drudis.2022.05.023] [Reference Citation Analysis]
8 Ding J, Guo Y. Recent Advances in Chitosan and its Derivatives in Cancer Treatment. Front Pharmacol 2022;13:888740. [DOI: 10.3389/fphar.2022.888740] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Saravanakumar K, Sathiyaseelan A, Park S, Kim S, Priya VV, Wang M. Monoclonal Antibody Functionalized, and L-lysine α-Oxidase Loaded PEGylated-Chitosan Nanoparticle for HER2/Neu Targeted Breast Cancer Therapy. Pharmaceutics 2022;14:927. [DOI: 10.3390/pharmaceutics14050927] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 许 晓. Effect of Peptide Modified Combined Chemotherapy Drugs and Gene Nanocomposites on Targeted Therapy of Laryngeal Cancer Stem Cells. WJCR 2022;12:136-146. [DOI: 10.12677/wjcr.2022.123019] [Reference Citation Analysis]
11 Madamsetty VS, Tavakol S, Moghassemi S, Dadashzadeh A, Schneible JD, Fatemi I, Shirvani A, Zarrabi A, Azedi F, Dehshahri A, Aghaei Afshar A, Aghaabbasi K, Pardakhty A, Mohammadinejad R, Kesharwani P. Chitosan: A versatile bio-platform for breast cancer theranostics. J Control Release 2021;341:733-52. [PMID: 34906606 DOI: 10.1016/j.jconrel.2021.12.012] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 13.0] [Reference Citation Analysis]
12 Shadbad MA, Asadzadeh Z, Derakhshani A, Hosseinkhani N, Mokhtarzadeh A, Baghbanzadeh A, Hajiasgharzadeh K, Brunetti O, Argentiero A, Racanelli V, Silvestris N, Baradaran B. A scoping review on the potentiality of PD-L1-inhibiting microRNAs in treating colorectal cancer: Toward single-cell sequencing-guided biocompatible-based delivery. Biomed Pharmacother 2021;143:112213. [PMID: 34560556 DOI: 10.1016/j.biopha.2021.112213] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]